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Abstract
In the past decade, great strides have been made in
the field of CNS tissue repair and expectations have been
raised that a cure of spinal paralysis is at hand. The two
broad categories of investigational approaches to spinal
regeneration are: (1) Enhancing the Regenerative Milieu of
the Cord and (2) Cellular and Tissue Transplantation.
Amongst the latter approaches, the early use of foetal cord
tissue has given way to the more sophisticated studies on
stem cell therapy and the implants of olfactory ensheating
cells. These have engendered considerable public interest
and are being offered as commercially available therapies in
clinics round the world to desperate patients. The internet
by allowing the dissemination of non-peer reviewed infor-
mation of experimental interventions catalyses this process.
Physicians must be informed of developments in this area to
offer appropriate advice and counsel to their patients.
Introduction
The standard of care in spinal cord injury with neu-
rological deficits has been prevention of secondary neural
injury followed by rehabilitation. The missing link between
these is an efficacious therapeutic intervention that would
promote neural regeneration and restoration of function.
Advances in molecular biology have extended to the study
of neural restoration and in the past decade great strides
have occurred in this area particularly spinal cord injury
research.1 However, the internet has allowed much unsub-
stantiated and unverified information to be available to
potential patients2 and it is imperative that physicians who
may be called upon to counsel such patients be familiar with
the relevant scientific and clinical information.
Approaches to Regeneration: Conventional wisdom holds
that the functional specialization of the central nervous sys-
tem (CNS) is established at the expense of its reparative
potential and in the adult spinal cord (SC) a complete injury
precludes any possibility of recovery of function. However,
observations of SC regeneration in amphibians and neona-
tal mammals give hope to investigators of replicating this in
adult mammals if the intricacies of the biology of neu-
rorestoration could be unraveled. In the past decade, great
strides have been made in the field of CNS tissue repair and
expectations have been raised that a cure of SC paralysis is
at hand. Indeed, a number of the lines of investigation being
perrsued in the laboratory have, in response to the demands
from eager patients, engendered a host of novel clinical
interventions. The two broad categories of investigational
approaches to SC regeneration are enhancing the regenera-
tive milieu of the cord and.cellular and tissue transplanta-
tion.
Inhibition at Glial Scar: Following a traumatic insult to
the SC, disrupted axons undergo Wallerian degeneration
and neurons may die in a process of necrosis and a more
delayed apoptosis. Surviving neurons initiate neurite
regrowth, but this regenerative activity is abortive and of no
functional significance after a complete injury. In a classical
experiment David and Aguayo in 1981 demonstrated that
when grafted with peripheral nerves, CNS axons in a
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sectioned SC would grow the full length of the graft but
failed to extend back into the distal stump of the cord.3 It
has since been established that CNS axons do have regener-
ative capabilities but are inhibited physically by the glial
scar that forms at the site of injury4 and biochemically by
inhibitory molecules upregulated by the injury.5 Enhancing
the regenerative milieu of the cord focuses on experimental
strategies that would attenuate the glial scar and block the
activity of growth inhibitory molecules and the receptors
that they bind to. Thus, the recruitment of reactive astro-
cytes and oligodendrocytes to the injury site has been inhib-
ited by x-irradiation6 and a direct injection of the cytoxic
ethidium bromide into the cord7 with enhanced axonal
regeneration in both experiments 
Inhibition in Extracellular Matrix: During neural devel-
opment, a variety of neurite-promoting and guidance mole-
cules exist in the extracellular matrix that are subsequently
downregulated in the adult CNS, permitting stable and com-
plex circuitry. Thus, in the adult CNS, the balance of factors
that support neurite growth and factors that inhibit neurite
growth shifts toward enhanced expression of growth-
inhibiting molecules. After SCI, many of the neurite guid-
ance factors are reexpressed and may provide strategies for
neurite growth if better understood.8 The extracellular
matrix proteins, particularly chondroitin sulfate proteogly-
cans, have received considerable attention in the search for
factors contributing to the failure of CNS regeneration and
have been associated with inhibion of neurite outgrowth and
collapse of the growth cone. Reports of functional recovery
in rats with dorsal column lesions treated with intrathecal
infusion of  chondroitinase ABC suggests that removal of
the chondroitin sulfate will be useful in regeneration.9
Although it is early in the field of SCI research for this area
to have made a contribution, the extracellular matrix pro-
teins will be an important consideration in a combinatorial
approach for successful regeneration of axons after injury.10
Biochemical Inhibition: A number of inhibitory factors
derived from the disrupted myelin have been isolated and
chemical antagonists to them encourage recovery from
experimental spinal injury. The best known inhibitory mol-
ecule is the high molecular weight NoGo.11 The IN-1  mon-
oclonal antibody, and NEP 1-40, a receptor blocker, which
neutralise the inhibitory protein activity of NoGo, have been
shown to encourage long tract regeneration12 and these
promising therapies  will soon be in phase I clinical trials.
Another myelin-derived growth-inhibitory protein, myelin-
associated glycoprotein (MAG), was identified and has
been characterized both in vitro and in vivo. One family of
the intracellular signaling molecules that regulate the inhi-
bition of neurite outgrowth that is drawing attention is the
Rho pathway,13 blockade of which has been shown to allow
axons to overcome the inhibitory milieu in vitro by revers-
ing the inhibitory signaling, not only by NoGo but also the
inhibitory proteoglycans present in the glial scar and to
regenerate after optic nerve and SC sections. Clinical trials
of a C3 Rho inhibitor (Cethrin) which gives sustained rever-
sal of Rho activation are underway. 
Nerve Growth Factors: Another approach to stimulating
axonal growth is to use local delivery of neurotropins eg.
Nerve Growth Factor (NGF) which stimulates the sprouting
of fine, primary afferent fiber systems and Neurotrophin 3
(NT-3) which has been demonstrated to potentiate corti-
cospinal growth.  It is obvious that subsets of nerve cells
will respond differently to each growth factor, so that a
combinatorial approach will be needed to encourage robust
regeneration of several systems.14 Recently, treatment with
intrathecal infusion of NGF, NT-3,   Gial Derived
Neurotrophic Factor (GDNF) and Brain Derived
Neurotrophic Factor (BDNF) demonstrated some success in
regeneration of cut dorsal roots into the dorsal root entry
zone.
Promoting Neurite Growth: Approaches that act through
direct intracellular mechanisms by targeting the down-
stream signalling molecules in the nerve cell body that pro-
mote axonal outgrowth, for example cAMP, should prove
useful.  Recent findings with inosine, a purine nucleoside
and cAMP that have demonstrated neurite outgrowth pro-
motion in vitro and in the rodent spinal cord are encourag-
ing.15 Currently in clinical trials for SCI is the compound
AIT-082 (Neotrofin),16 a synthetic hypoxanthine derivative
containing a para-aminobenzoic acid moiety which had
been shown to promote both axonal sprouting and the pro-
duction of NGF, NT-3, and bFGF in astrocytes in culture
systems and in vivo. 
Encouraging scavenging by macrophages could
clear the inhibitory factors engendered by the disrupted
myelin of the traumatized SC and this rationale underlies
one of the multicentre clinical trial that has entered Phase II
(Proneuron) in a number of countries. The macrophages
from the patient's own blood (autologous macrophages) are
activated by exposure to skin and implanted at the site of the
spinal injury in an attempt to encourage regenerative growth
without eliciting an immune response.17 A number of other
cellular and tissue transplantation strategies have been
applied in animals and increasingly in humans to bridge the
physical gap resulting from the cord injury and the chal-
lenge has been to find the bridging graft that would be per-
missive to axonal growth and integrate efficiently to permit
function without any tissue or immune response.18 Early
results of foetal tissue grafting in rodents and primates were
encouraging and subsequently there are several clinical tri-
als in Sweden, Florida, Russia, and China in which foetal
tissue en bloc has been used in patients with SC injury with
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good graft survival and even integration but disappointing
return of function. However, foetal grafts have been useful
in treating posttraumatic syringomyelia.19
Schwann Cell Implants: Implants into the injury gap com-
posed of Schwann cells,20 which form the myelin in the
peripheral nervous system where regeneration does occur,
or multiple grafting of intercostal nerves3 in rodent models
of spinal injury are both approaches in which some regener-
ating nerve cell axons have been able to grow across the
gap, but penetration into the host tissue has not been impres-
sive. Some functional recovery was demonstrated in both
approaches. The Schwann cells can be cultured and purified
with relative ease and the experimental literature attests to
their facilitatory role in neural regeneration but they do not
cohabit well with astrocytes. When grafted into the spinal
cord, they evoke astroglial scarring and the grafts soon get
walled off, restricting access of regeneration fibres to the
implant. No human trial of schwann cell implants have been
reported.
Animal experiments in which peripheral nerves are
used as bridges have shown that these grafts induce and sup-
port axonal outgrowth over long distances in the spinal
cord. Clinical trials are in progress in Ecuador and at the
University of Sao Paulo, where more than 100 patients have
received nerve bridges.2 Reports of results in peer reviewed
literature are sparse though some patients offer effusive
endorsements over the internet.
Olfactory Ensheathing Cells (OEG): These are very
unusual cell type that normally reside with the olfactory
nerve in the nasal mucosa and in the olfactory bulb and are
a promising regenerative therapy for spinal cord injury.21
The olfactory nerve is the only cranial nerve that continu-
ously regenerates in adult mammals and this ability has
been credited to the presence of these cells.22 OEG cells
appear to be specialized for enhancing axonal regeneration.
First, they are migratory cells that seem to be attracted to
growing axons. Second, they can form multipolar cells with
long processes that express a variety of axon-stimulating
cell adhesion molecules and seemingly serve a guidance
function. Third, they can myelinate axons, hence the word
"ensheathing" in their name. At least half a dozen laborato-
ries have now reported that these cells will facilitate func-
tional neural regeneration when transplanted to the brain or
spinal cord in rodents 21 and these findings, being striking is
some reports,23 have driven patient interventions. Implants
of OEG are clinically available in Beijing24 where over 600
patients from round the world have been grafted and
Lisbon25 where the experience extends to some 20 patients
but from neither centre have the results been reported ade-
quately. Workers in Brisbane have initiated human trials
after extensive animal experimentation and the preliminary
results demonstrating the safety of the procedure have
recently been published.26
More recent studies on the biology of OEGs have
tempered the earlier enthusiasm and caution is being
advised by authorities in the clinical application of implan-
tation. 
Stem Cells: Human neural progenitor cells and embryonic
stem cells have been used in rodent spinal injury models27
and having demonstrated functional recovery have engen-
dered much anticipation in the lay public as heralding the
cure to spinal paralysis.28 Although considerable work in
the field of stem cell biology remains, there are some clini-
cal trials in Russia in which foetal stem cells are used as
transplant sources for chronic SCI or in combination with
olfactory ensheathing glial cells. Stem cell therapies have
been given greater impetus by the isolation and culturing of
pluripotential neural cell lines from bone marrow,29 blood
and umbilical cord blood.30 However, despite extensive
efforts in spinal injured patients, no verified case of substan-
tive  recovery has been reported in the peer-reviewed litera-
ture. Results in SC injured patients infused with  retrodiffer-
entiated stem cells derived from the patients blood in  the
method of Dr Ilham Abuljadayel working in Karachi,31 have
been similarly disappointing.32 Other transplant sources
include transposition of the omentum  and transplantation of
embryonic shark cells in Mexico. These latter two
approaches are generally viewed as lacking serious scientif-
ic merit.33
Bridging the Gap: Advances in the field of biomatrix mate-
rial have provided opportunities to bridge the gap with arti-
ficial material, such as biodegradable hydrogels or combi-
nations of hydrogels and cells that may promote regenera-
tion.34 Desired properties of a synthetic bridge are to pro-
vide simultaneously a physical substrate for axonal attach-
ment and growth without triggering antigenic host reac-
tions. Although this approach is in its infancy, great strides
are possible with polymer chemistry.
Conclusion
Scientific work of the past decade has demonstrated
a number of approaches to enhancing SC regeneration to be
promising in rodent models and the challenge is to translate
these into treatments for human patients.35 Premature trans-
lation of animal work to humans who are often desperate
and feel they have nothing to lose, harms them by preclud-
ing them from future trials of developing therapies and
detracts from the promise that such research holds for future
generations.
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